Patents by Inventor Kevin GELSTON

Kevin GELSTON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230087487
    Abstract: One aspect of the present disclosure is directed to a method of delivering the RNAi agents to or through a skin. Another aspect of the present disclosure is directed to a method of reducing expression or translation of a target gene within a stratum corneum layer, an epidermis layer, a dermis layer, a subcutaneous tissue layer, or a muscle tissue. Another aspect of the present disclosure is directed to a topical composition, comprising the RNAi agents or a pharmaceutically acceptable salt thereof, and an ionic liquid in an amount sufficient to allow a therapeutically effective amount of the RNAi agents to reach a target depth within or beyond the skin.
    Type: Application
    Filed: December 9, 2020
    Publication date: March 23, 2023
    Inventors: Nitin JOSHI, Kevin GELSTON, Marina SHEVACHMAN
  • Publication number: 20220401447
    Abstract: One aspect of the present disclosure is directed to a method of delivering tofacitinib to or through a skin. Another aspect of the present disclosure is directed to a method of locally inhibiting activity of at least one of JAK-1, JAK-2, TYK-2, and JAK-3 within an epidermis layer, a dermis layer, a subcutaneous tissue layer, or a muscle tissue. Another aspect of the present disclosure is directed to a topical composition, comprising tofacitinib or a pharmaceutically acceptable salt thereof, and an ionic liquid in an amount sufficient to allow a therapeutically effective amount of tofacitinib to reach a target depth within or beyond the skin.
    Type: Application
    Filed: November 7, 2020
    Publication date: December 22, 2022
    Inventors: Nitin JOSHI, Kevin GELSTON, Marina SHEVACHMAN
  • Publication number: 20220280763
    Abstract: A transdermal drug delivery device includes a reservoir, a transdermal membrane, a piston, a control rod, a spring, and a rotational cam. The reservoir is configured to hold a formulation. The transdermal membrane is configured to allow the formulation from the reservoir to pass therethrough. The piston is configured to move into the reservoir. The control rod is attached to the piston and includes a plurality of teeth thereon. The spring is configured to apply force to the control rod in the direction of the reservoir. The rotational cam has a first camming surface and a second camming surface that are configured to engage with the plurality of teeth. The rotational cam, when rotated, is configured to disengage the first camming surface from a first tooth of the plurality of teeth, thereby allowing the spring to advance the piston into the reservoir to expel the formulation onto the transdermal membrane.
    Type: Application
    Filed: March 24, 2022
    Publication date: September 8, 2022
    Inventors: Andrew L. JOHNSTON, Michael P. SCHALLER, Bryce PETERSON, Kevin GELSTON
  • Patent number: 11285306
    Abstract: A transdermal drug delivery device includes a reservoir, a transdermal membrane, a piston, a control rod, a spring, and a rotational cam. The reservoir is configured to hold a formulation. The transdermal membrane is configured to allow the formulation from the reservoir to pass therethrough. The piston is configured to move into the reservoir. The control rod is attached to the piston and includes a plurality of teeth thereon. The spring is configured to apply force to the control rod in the direction of the reservoir. The rotational cam has a first camming surface and a second camming surface that are configured to engage with the plurality of teeth. The rotational cam, when rotated, is configured to disengage the first camming surface from a first tooth of the plurality of teeth, thereby allowing the spring to advance the piston into the reservoir to expel the formulation onto the transdermal membrane.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: March 29, 2022
    Assignee: Morningside Venture Investments Limited
    Inventors: Andrew L. Johnston, Michael P. Schaller, Bryce Peterson, Kevin Gelston
  • Publication number: 20190336738
    Abstract: A transdermal drug delivery device includes a reservoir, a transdermal membrane, a piston, a control rod, a spring, and a rotational cam. The reservoir is configured to hold a formulation. The transdermal membrane is configured to allow the formulation from the reservoir to pass therethrough. The piston is configured to move into the reservoir. The control rod is attached to the piston and includes a plurality of teeth thereon. The spring is configured to apply force to the control rod in the direction of the reservoir. The rotational cam has a first camming surface and a second camming surface that are configured to engage with the plurality of teeth. The rotational cam, when rotated, is configured to disengage the first camming surface from a first tooth of the plurality of teeth, thereby allowing the spring to advance the piston into the reservoir to expel the formulation onto the transdermal membrane.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Inventors: Andrew L. JOHNSTON, Michael P. SCHALLER, Bryce PETERSON, Kevin GELSTON